Pegylated epoetin alfa - Center of Molecular Immunology
Alternative Names: Pegylated hrEPOLatest Information Update: 28 Oct 2020
At a glance
- Originator Center of Molecular Immunology
- Class Antianaemics; Erythropoietins; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia; Neurological disorders
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Anaemia in Cuba
- 28 Oct 2020 No recent reports of development identified for preclinical development in Neurological-disorders(Prevention) in Cuba (Intranasal)
- 22 Sep 2016 Preclinical trials in Anaemia in Cuba (unspecified route) before September 2016 (CIMAB pipeline; January 2016)